GlassScriptPhysician profile
Eric J Castleman
NPI 1760491344
$6,690.13
in general payments reported to CMS, 2019-2025
38 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $363 · 2021: $360 · 2022: $393 · 2023: $865 · 2024: $1,456 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $935.00 | 2019-2025 | Avvigo Guidance System, Rotapro, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $877.48 | 2019-2025 | |
| Pfizer INC. | $656.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $640.77 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $396.14 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $372.12 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $308.86 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.18 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $282.12 | 2019-2025 | Farxiga, Wainua |
| Alnylam Pharmaceuticals INC. | $226.94 | 2020-2025 | Amvuttra |
| Novo Nordisk INC | $194.70 | 2021-2025 | Wegovy, Ozempic |
| Shockwave Medical, INC | $186.79 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $137.24 | 2019-2023 | |
| Abbott Laboratories | $100.18 | 2020-2025 | Navitor, Amplatzer Amulet, Aveir |
| Kiniksa Pharmaceuticals International, Plc | $100.16 | 2024 | Arcalyst |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $91.10 | 2020-2025 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $83.44 | 2023-2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $82.54 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $69.49 | 2023-2025 | Verquvo |
| Cardiva Medical, INC. | $68.64 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f, Savvywire |
| Kestra Medical Technology Services, INC. | $61.98 | 2024-2025 | Assure Wcd |
| Biotronik INC. | $59.98 | 2020-2022 | |
| Teleflex LLC | $52.24 | 2019-2020 | |
| Bridgebio Pharma, INC. | $50.34 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $39.92 | 2019-2021 | |
| Amarin Pharma, INC. | $35.22 | 2019 | |
| Altathera Pharmaceuticals LLC | $29.54 | 2025 | Sotalol Hydrochloride |
| Akcea Therapeutics, INC. | $28.74 | 2019 | |
| Bardy Diagnostics, INC. | $28.34 | 2021 | |
| Heartflow, INC. | $28.07 | 2025 | |
| Scpharmaceuticals INC. | $24.02 | 2025 | |
| Abiomed | $23.53 | 2019 | |
| Cleerly, INC. | $23.02 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $22.07 | 2025 | |
| Esperion Therapeutics, INC. | $21.21 | 2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $19.83 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.75 | 2023 | Arcalyst |
| Astellas Pharma US INC | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Castleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.